Advanced

RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Westborg , Inger ; Albrecht, Susanne and Rosso, Aldana LU (2017) In Retina 37(11). p.2035-2046
Abstract

PURPOSE:: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice. METHODS:: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patientsʼ characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years. RESULTS:: The treatment outcome depends on the visual acuity at the first visit.... (More)

PURPOSE:: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice. METHODS:: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patientsʼ characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years. RESULTS:: The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug. CONCLUSION:: Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Retina
volume
37
issue
11
pages
2035 - 2046
publisher
Lippincott Williams & Wilkins
external identifiers
  • scopus:85011279074
ISSN
0275-004X
DOI
10.1097/IAE.0000000000001431
language
English
LU publication?
yes
id
c508b2d6-63b5-4f2f-9c9c-260e86afc8a0
date added to LUP
2017-02-14 13:18:58
date last changed
2018-05-06 04:30:49
@article{c508b2d6-63b5-4f2f-9c9c-260e86afc8a0,
  abstract     = {<p>PURPOSE:: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice. METHODS:: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patientsʼ characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years. RESULTS:: The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug. CONCLUSION:: Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.</p>},
  author       = {Westborg , Inger  and Albrecht, Susanne and Rosso, Aldana},
  issn         = {0275-004X},
  language     = {eng},
  month        = {01},
  number       = {11},
  pages        = {2035--2046},
  publisher    = {Lippincott Williams & Wilkins},
  series       = {Retina},
  title        = {RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION},
  url          = {http://dx.doi.org/10.1097/IAE.0000000000001431},
  volume       = {37},
  year         = {2017},
}